MARKET

SNGXW

SNGXW

SOLIGENIX WT
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.4100
-0.0400
-8.89%
Opening 15:38 03/02 EST
OPEN
0.4150
PREV CLOSE
0.4500
HIGH
0.4200
LOW
0.4100
VOLUME
14.21K
TURNOVER
--
52 WEEK HIGH
1.120
52 WEEK LOW
0.1600
MARKET CAP
--
P/E (TTM)
-0.6557
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
BRIEF-Soligenix Provides Highlights And Upcoming Catalysts In Corporate Update Letter
reuters.com · 6d ago
BRIEF-Soligenix Completes Enrollment In Phase 3 Clinical Trial Of Sgx942 For Treatment Of Oral Mucositis
* SOLIGENIX COMPLETES ENROLLMENT IN ITS PIVOTAL PHASE 3 CLINICAL TRIAL OF SGX942 FOR THE TREATMENT OF ORAL MUCOSITIS
Reuters · 06/24/2020 11:19
BRIEF-Soligenix To Join Russell Microcap® Index
* SOLIGENIX TO JOIN RUSSELL MICROCAP® INDEX Source text for Eikon: Further company coverage:
Reuters · 06/22/2020 11:28
BRIEF-Soligenix Announces Recent Accomplishments And Q1 2020 Financial Results
* SOLIGENIX ANNOUNCES RECENT ACCOMPLISHMENTS AND FIRST QUARTER 2020 FINANCIAL RESULTS
Reuters · 05/15/2020 11:20
BRIEF-Soligenix Announces Positive Phase 3 Flash Study Demonstrates Increased Efficacy With Continued Treatment In Patients With Cutaneous T-Cell Lymphoma
* SOLIGENIX ANNOUNCES POSITIVE PHASE 3 FLASH STUDY DEMONSTRATES INCREASED EFFICACY WITH CONTINUED TREATMENT IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA
Reuters · 04/30/2020 12:31
BRIEF-Soligenix Announces Exclusive Licensing Agreement For Novel Vaccine Adjuvant From Btg Specialty Pharma
* SOLIGENIX ANNOUNCES EXCLUSIVE LICENSING AGREEMENT FOR NOVEL VACCINE ADJUVANT FROM BTG SPECIALTY PHARMACEUTICALS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)
Reuters · 04/16/2020 11:43
BRIEF-Soligenix Receives European Patent For Therapeutic Use Of Synthetic Hypericin To Treat Cutaneous T-Cell Lymphoma
* SOLIGENIX RECEIVES EUROPEAN PATENT FOR THERAPEUTIC USE OF SYNTHETIC HYPERICIN TO TREAT CUTANEOUS T-CELL LYMPHOMA Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)
Reuters · 04/06/2020 11:29
BRIEF-Soligenix And University Of Hawaiʻi At Mānoa Initiate Work On Novel Coronavirus Vaccine For Covid-19
* SOLIGENIX AND UNIVERSITY OF HAWAIʻI AT MĀNOA INITIATE WORK ON NOVEL CORONAVIRUS VACCINE FOR COVID-19 Source text for Eikon: Further company coverage:
Reuters · 03/23/2020 13:22
More
Forecast
EPSBVPSCFPS
No Data
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SNGXW. Analyze the recent business situations of SOLIGENIX WT through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
About SNGXW
Soligenix, Inc. (Soligenix) is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two business segments: Specialized BioTherapeutics and Public Health Solution. Soligenix’s Specialized BioTherapeutics business segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma (CTCL). The Public Health Solutions business segment includes active development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious disease. CTCL is its innate defense regulator technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.

Webull offers kinds of Soligenix Inc stock information, including NASDAQ:SNGXW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNGXW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SNGXW stock methods without spending real money on the virtual paper trading platform.